DHANUKA Dhanuka Agritech Q3 FY25 results (Oct–Dec 2024) and concall
Dhanuka Agritech delivered a robust Q3 FY25 performance with double-digit revenue and profit growth, driven by new product introductions and strong market execution. The company also made a significant strategic acquisition of international rights for two agrochemical molecules from Bayer, signaling its intent for global expansion. Despite challenges from adverse weather and commodity price pressures, particularly affecting generic products, Dhanuka maintained strong margins and outlined plans for future growth through product innovation and market diversification.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 654 | 445 |
| EBITDA | 160 | 76 |
| Net profit | 118 | 55 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
